LONDON, April 2, 2026 /PRNewswire/ -- Folly, the first biotech-powered hair supplement, today announced its global launch alongside a follow-on investment led by Khosla Ventures. The investment will accelerate global commercialization of the breakthrough encapsulation platform and expansion into new wellness categories.
Folly delivers 30+ clinically studied ingredients in a gummy form factor, at dosages previously associated only with pills and capsules, using Folly Microspheres, a proprietary microencapsulation system developed by . It is the first hair supplement to apply drug-delivery science to solve what the company calls "the supplement industry's consistency crisis."
Most hair supplements use similar buzzword ingredients: biotin, vitamins, pumpkin seed oil. On paper, many of them look comparable.
Women cycle through products that look promising but either don't deliver meaningful dosing or are too cumbersome to stay on long enough to see results.
Folly delivers clinically studied ingredients at meaningful levels, not beauty-level doses designed for marketing appeal.
To make this possible in a gummy format, Folly developed a that helps stabilize sensitive actives during production and digestion. This allows the gummy to maintain higher ingredient loading than typical hair gummies, without compromising taste or daily usability.
In a 300-person consumer perception study, women who used Folly daily for at least 30 days reported:
Folly launches in April 2026 in the U.S. and U.K., with expansion across Europe and Asia throughout 2026.
Visit: / @FollyNutrition
View original content: https://www.prnewswire.co.uk/news-releases/folly-launches-first-pill-strength-hair-health-gummy-302731595.html